MRC-5 Cells

MRC-5 cells, a human lung fibroblast cell line derived from the lung tissue of a 14-week-old male fetus in 1966, are extensively utilized in the production of certain vaccines, including those for hepatitis A, polio, rabies, and more. The susceptibility to various human viruses, notably human poliovirus 1, herpes simplex virus, and vesicular stomatitis virus underscores the role of MRC5 cells in the discovery of antivirals, viral vaccines, vaccine safety and virus replication. MRC-5 and WI-38 cell lines are still used in producing vaccines for varicella, rubella, hepatitis A, and a version of rabies vaccine today. Recently, MRC-5 cells were modified to express the ACE2 receptor, and have been key in SARS research. The modified MRC5 human ace2 cells allow scientists to study how the SARS-CoV virus enters and replicates in host cells. This work has been vital for understanding the virus's behavior and developing targeted antiviral agents and treatments. The MRC5 fetal cell line's utility extends beyond vaccine production to include potential roles in cancer research, with the cell line being employed in studies exploring the tumor microenvironment and cancer cell interactions, owing to their capability to differentiate into multiple cell types, including osteocytes and chondrocytes. This has led to speculation about their similarity to mesenchymal stem cells (MSCs), given their fibroblast-like morphology and maintenance of a normal diploid karyotype over extensive in vitro expansion. Human cells, Lung, Growth Conditions: Adherent, Biosafety level: BSL 1